CVRX logo

CVRx (CVRX) Company Overview

Profile

Full Name:

CVRx, Inc.

Sector:

Healthcare

Country:

United States

IPO:

June 30, 2021

Indexes:

Not included

Description:

CVRx is a medical device company focused on innovative therapies for heart failure and hypertension. Their flagship product, Barostim, is a neuromodulation device that helps regulate blood pressure and improve heart function, offering a non-pharmacological treatment option for patients with cardiovascular conditions.

Key Details

Price

$13.99

Annual Revenue

$51.29 M(+30.53% YoY)

Annual EPS

-$2.65(-33.17% YoY)

Annual ROE

-81.58%

Beta

1.59

Events Calendar

Earnings

Next earnings date:

Apr 30, 2025

Recent quarterly earnings:

Feb 4, 2025

Recent annual earnings:

Feb 4, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 17, 25 Craig-Hallum
Buy
Jan 14, 25 William Blair
Outperform
Dec 9, 24 Canaccord Genuity
Buy
Nov 4, 24 Craig-Hallum
Buy
Oct 30, 24 Piper Sandler
Overweight
Oct 30, 24 Lake Street
Buy
Oct 30, 24 Canaccord Genuity
Buy
Oct 23, 24 Cantor Fitzgerald
Overweight
Sep 10, 24 Cantor Fitzgerald
Overweight
Aug 26, 24 Lake Street
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRX
zacks.comFebruary 4, 2025

CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago.

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
CVRX
globenewswire.comJanuary 21, 2025

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
CVRX
zacks.comJanuary 16, 2025

CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CVRX
globenewswire.comDecember 23, 2024

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast.

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRX
globenewswire.comNovember 20, 2024

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
CVRX
seekingalpha.comOctober 29, 2024

CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call.

CVRx announces new CPT® Category I codes for Barostim
CVRx announces new CPT® Category I codes for Barostim
CVRx announces new CPT® Category I codes for Barostim
CVRX
globenewswire.comOctober 18, 2024

MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
CVRX
globenewswire.comOctober 15, 2024

MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
CVRX
zacks.comSeptember 16, 2024

CVRx announces the publication of positive study data for its Barostim therapy.

CVRx Announces Appointment of Two New Board Members
CVRx Announces Appointment of Two New Board Members
CVRx Announces Appointment of Two New Board Members
CVRX
globenewswire.comSeptember 3, 2024

Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members

FAQ

  • What is the ticker symbol for CVRx?
  • Does CVRx pay dividends?
  • What sector is CVRx in?
  • What industry is CVRx in?
  • What country is CVRx based in?
  • When did CVRx go public?
  • Is CVRx in the S&P 500?
  • Is CVRx in the NASDAQ 100?
  • Is CVRx in the Dow Jones?
  • When was CVRx's last earnings report?
  • When does CVRx report earnings?
  • Should I buy CVRx stock now?

What is the ticker symbol for CVRx?

The ticker symbol for CVRx is NASDAQ:CVRX

Does CVRx pay dividends?

No, CVRx does not pay dividends

What sector is CVRx in?

CVRx is in the Healthcare sector

What industry is CVRx in?

CVRx is in the Medical Devices industry

What country is CVRx based in?

CVRx is headquartered in United States

When did CVRx go public?

CVRx's initial public offering (IPO) was on June 30, 2021

Is CVRx in the S&P 500?

No, CVRx is not included in the S&P 500 index

Is CVRx in the NASDAQ 100?

No, CVRx is not included in the NASDAQ 100 index

Is CVRx in the Dow Jones?

No, CVRx is not included in the Dow Jones index

When was CVRx's last earnings report?

CVRx's most recent earnings report was on Feb 4, 2025

When does CVRx report earnings?

The next expected earnings date for CVRx is Apr 30, 2025

Should I buy CVRx stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions